May 2 (Reuters) - Animal healthcare company Zoetis surpassed analysts' expectations for first-quarter profit on Thursday, helped by strong demand for its medicines and vaccines for pets. Zoetis deals with vaccines, medicines and diagnostic solutions for animals and manufactures products for livestock and fish, which it markets in more than 40 countries. The company posted adjusted profit of $1.38 per share for the first quarter, beating analysts' average estimate of $1.34 per share, according to LSEG data. Shares of the company rose 4% to $163.52 in premarket trading. Zoetis had said in February it expects companion animal to be the primary growth driver in 2024, helped in part by strong demand for its osteoarthritis pain medication — Librela for dogs and Solensia for cats. The New Jersey-based company posted first-quarter revenue of $2.19 billion, compared with analysts' estimate of $2.13 billion. Revenue in its companion animal segment, which sells vaccines and medicines for dogs, cats and horses, rose 18% to $1.45 billion, also beating estimates of $1.37 billion. Zoetis attributed the rise in revenue to growth in its flea, tick and heartworm combination product and its pet pain products. The company, however, expects its 2024 adjusted profit to be between $5.71 and $5.81 per share, compared with its previous forecast range of $5.74 to $5.84 per share. (Reporting by Sneha S K in Bengaluru; Editing by Shilpi Majumdar)
Zoetis beats profit estimates on strong demand for pet products
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...